174 related articles for article (PubMed ID: 38137452)
21. Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Carcinoma: A Real-World Study.
Zhang M; Li L; Zhang S; Zhu W; Yang S; Di G; Ma X; Yang H
Biomed Res Int; 2020; 2020():3208391. PubMed ID: 32461977
[TBL] [Abstract][Full Text] [Related]
22. Ductal carcinoma in situ on stereotactic biopsy of suspicious breast microcalcifications: Expression of SPARC (Secreted Protein, Acidic and Rich in Cysteine) can predict postoperative invasion.
Szynglarewicz B; Kasprzak P; Donizy P; Biecek P; Halon A; Matkowski R
J Surg Oncol; 2016 Oct; 114(5):548-556. PubMed ID: 27439354
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
24. Expression of secreted protein acidic and rich in cysteine is an independent prognostic indicator of a poor clinical outcome in oropharyngeal carcinoma patients.
Yoshida S; Wakisaka N; Kondo S; Moriyama-Kita M; Hirai N; Endo K; Tsuji A; Nakanishi Y; Murono S; Yoshizaki T
Acta Otolaryngol; 2016; 136(2):189-94. PubMed ID: 26523779
[TBL] [Abstract][Full Text] [Related]
25. HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer.
Cherifi F; Da Silva A; Johnson A; Blanc-Fournier C; Abramovici O; Broyelle A; Levy C; Allouache D; Hrab I; Segura C; Morel A; Villemin M; Boscher C; Dubot-Poitelon C; Rottier P; Lequesne J; Emile G
BMC Cancer; 2022 Oct; 22(1):1081. PubMed ID: 36266623
[TBL] [Abstract][Full Text] [Related]
26. Increased SPARC expression is associated with neoadjuvant therapy in resectable pancreatic ductal adenocarcinoma.
Hartley C; Rowan D; Chen X; Gomez-Arellano L; West AM; Oshima K; Mackinnon AC
Pract Lab Med; 2020 Aug; 21():e00171. PubMed ID: 32548230
[TBL] [Abstract][Full Text] [Related]
27. Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial.
Futamura M; Nagao Y; Ishihara K; Takeuchi M; Nakada T; Kawaguchi Y; Asano M; Kumazawa I; Shiroko T; Morimitsu K; Mori R; Nawa M; Shimokawa T; Yoshida K
Breast Cancer; 2017 Jul; 24(4):615-623. PubMed ID: 28050738
[TBL] [Abstract][Full Text] [Related]
28. Secreted protein acidic and rich in cysteine gene variants: Impact on susceptibility and survival of hepatocellular carcinoma patients.
Darweesh SK; Abd Alziz RA; Omar H; Sabry D; Fathy W
J Gastroenterol Hepatol; 2019 Aug; 34(8):1424-1431. PubMed ID: 30422339
[TBL] [Abstract][Full Text] [Related]
29. The value of potential immunohistochemical biomarkers and clinicopathological findings in predicting response to neoadjuvant chemotherapy in breast cancer.
Akay E; Eren SK; Özhan N; Arslan A; Karaman H
Eur Rev Med Pharmacol Sci; 2022 Oct; 26(19):7070-7083. PubMed ID: 36263555
[TBL] [Abstract][Full Text] [Related]
30. Complete Metabolic Response on Interim
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
[TBL] [Abstract][Full Text] [Related]
31. Luminal B, Human Epidermal Growth Factor Receptor 2 (HER2/neu), and Triple-Negative Breast Cancers Associated With a Better Chemotherapy Response Than Luminal A Breast Cancers in Postneoadjuvant Settings.
Hashmi AA; Bukhari U; Najam J; Dowlah T; Ali AH; Diwan MA; Anjali F; Sham S; Zia S; Irfan M
Cureus; 2023 Jun; 15(6):e40066. PubMed ID: 37425505
[TBL] [Abstract][Full Text] [Related]
32. HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer.
de Moura Leite L; Cesca MG; Tavares MC; Santana DM; Saldanha EF; Guimarães PT; Sá DDS; Simões MFE; Viana RL; Rocha FG; Loose SK; Silva SF; Pirolli R; Fogassa CAZ; Mattos BRS; Campos FAB; Sanches SM; de Lima VCC; Pondé NF
Breast Cancer Res Treat; 2021 Nov; 190(1):155-163. PubMed ID: 34409551
[TBL] [Abstract][Full Text] [Related]
33. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
34. Tetrahydrocurcumin Chemosensitizes Breast Cancer to Albumin-Bound Paclitaxel by Enhancing SPARC Expression through Demethylation.
Qiu D; Li X; Liu Y; Bao X; Ma L
J Oncol; 2022; 2022():7961537. PubMed ID: 36157225
[TBL] [Abstract][Full Text] [Related]
35. HER2-low status may predict poor neoadjuvant chemotherapy response in HR-negative breast cancer: a real-world multicenter study.
Xu W; Jiang Y; Xu L; Li C; Wang J; Liu Z; Xue D; Gu Y; Zhong Z; He S; Wang S; Zhou W; Pan H
Jpn J Clin Oncol; 2023 Jun; 53(6):463-471. PubMed ID: 36757139
[TBL] [Abstract][Full Text] [Related]
36. Quantification of Ki67 Change as a Valid Prognostic Indicator of Luminal B Type Breast Cancer After Neoadjuvant Therapy.
Tan S; Fu X; Xu S; Qiu P; Lv Z; Xu Y; Zhang Q
Pathol Oncol Res; 2021; 27():1609972. PubMed ID: 34987312
[No Abstract] [Full Text] [Related]
37. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status.
Desai NP; Trieu V; Hwang LY; Wu R; Soon-Shiong P; Gradishar WJ
Anticancer Drugs; 2008 Oct; 19(9):899-909. PubMed ID: 18766004
[TBL] [Abstract][Full Text] [Related]
38. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Loibl S; Müller BM; Roller M; Denkert C; Komor M; Schlüns K; Blohmer JU; Budczies J; Gerber B; Noske A; du Bois A; Weichert W; Jackisch C; Dietel M; Richter K; Kaufmann M; von Minckwitz G
Breast Cancer Res; 2009; 11(5):R69. PubMed ID: 19758440
[TBL] [Abstract][Full Text] [Related]
39. The high stromal SPARC expression is independently associated with poor survival of patients with resected pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine in combination with S-1 or adjuvant gemcitabine alone.
Shintakuya R; Kondo N; Murakami Y; Uemura K; Nakagawa N; Okano K; Takahashi S; Sueda T
Pancreatology; 2018 Mar; 18(2):191-197. PubMed ID: 29295776
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Significance of SPARC Expression in Breast Cancer: A Meta-Analysis and Bioinformatics Analysis.
Shi S; Ma HY; Han XY; Sang YZ; Yang MY; Zhang ZG
Biomed Res Int; 2022; 2022():8600419. PubMed ID: 35211625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
